REVIEW ARTICLE

A Literature Review of Most Common Symptoms in Respiratory Therapist's Practice: How to Manage Dyspnea in Interstitial Lung Disease

Mohankumar Thekkinkattil

Received on: 18 December 2023; *Accepted on:* 30 January 2024; *Published on:* xxxx

Abstract

Dyspnea is a distressing symptom prevalent in interstitial lung disease (ILD) patients, significantly affecting their quality of life. Understanding the multifaceted nature of dyspnea in ILD is crucial for comprehensive patient care. This article supplies an in-depth exploration of dyspnea in ILD, covering its causes, pathophysiological mechanisms, diagnostic strategies, and treatment approaches. The causes of dyspnea in ILD encompass a spectrum of factors including restrictive lung function, alveolar damage, impaired gas exchange, pulmonary vascular involvement, inflammation, and scarring. These factors collectively contribute to the challenging symptomatology experienced by ILD patients. Pathophysiologically, dyspnea in ILD stems from altered lung mechanics, compromised gas exchange due to fibrotic changes, pulmonary vascular remodeling, and intricate neural pathways involved in dyspnea perception. Diagnosis of dyspnea in ILD necessitates a comprehensive approach involving clinical history, physical examinations, pulmonary function tests (PFTs), imaging studies, biomarkers, and functional assessments like cardiopulmonary exercise testing (CPET). Treatment strategies encompass a multidisciplinary approach, integrating pharmacological interventions such as corticosteroids, immunosuppressants, and antifibrotic agents, alongside pulmonary rehabilitation, oxygen therapy, and in severe cases, lung transplantation. This article highlights recent research developments, clinical trials, and advancements in understanding and managing dyspnea in ILD patients. Continual exploration and personalized approaches are imperative to alleviate the burden of dyspnea and enhance the lives of those affected by ILD.

Keywords: Corticosteroids, Dyspnea, Interstitial, Lung disease.

Indian Journal of Respiratory Care (2024): 10.5005/jp-journals-11010-1092

Introduction

Dyspnea, characterized by the sensation of breathlessness or difficulty in breathing, is a cardinal symptom in various respiratory diseases, notably interstitial lung disease (ILD). Studies consistently highlight dyspnea as a pervasive and distressing symptom experienced by ILD patients.[1] ILD encompasses a diverse group of parenchymal lung disorders characterized by inflammation and fibrosis of the interstitial tissue. This includes idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis, sarcoidosis, and other interstitial pneumonias.[2] The prevalence of dyspnea in ILD is substantial, affecting up to 90% of patients across different ILD subtypes.[1,3] Dyspnea's impact on the quality of life for ILD patients is profound, with studies linking its severity to reduced physical activity, impaired emotional well-being, and increased mortality risk.[4,5] In a study by Swigris et al., the St George's Respiratory Questionnaire and the University of California San Diego Shortness of Breath Questionnaire demonstrated the considerable impairment of health-related quality of life due to dyspnea in ILD patients.[6] Additionally, Nishiyama et al. reported a significant correlation between dyspnea severity and limitations in daily activities in individuals with ILD.[7]

Causes of Dyspnea in Interstitial Lung Disease

The interplay among multiple factors contributes significantly to dyspnea, a hallmark symptom in ILD.

Department of Pulmonology, Critical Care and Sleep Medicine, One Care Medical Center, Coimbatore, Tamil Nadu, India

Corresponding Author: Mohankumar Thekkinkattil, Department of Pulmonology, Critical Care and Sleep Medicine, One Care Medical Center, Coimbatore, Tamil Nadu, India, Phone: +91 9894622018, e-mail: tmkdr@hotmail.com

How to cite this article: Thekkinkattil M. A Literature Review of Most Common Symptoms in Respiratory Therapist's Practice: How to Manage Dyspnea in Interstitial Lung Disease. Indian J Respir Care 2024;https://doi.org/10.5005/jp-journals-11010-1092.

Source of support: Nil

Conflict of interest: Dr Mohankumar Thekkinkattil is associated as the Section Editorial Board member of this journal and this manuscript was subjected to this journal's standard review procedures, with this peer review handled independently of this editorial board member and his research group.

Restrictive Lung Function

The ILD induces structural changes in the lung parenchyma, leading to reduced compliance and lung expansion. The ensuing restrictive pattern impedes proper lung inflation and expiration, culminating in dyspnea.[8]

Alveolar Damage and Fibrosis

Progressive fibrotic changes in the interstitial spaces disrupt the alveolar architecture, impairing gas exchange efficiency.

Alveolar damage, characterized by extensive fibrosis and scarring, reduces the lung's capacity for oxygen uptake and carbon dioxide elimination, exacerbating dyspnea.[9]

Gas Exchange Impairment

The ILD-associated fibrosis and inflammation compromise the delicate balance of gas exchange at the alveolar-capillary interface. This impairment leads to ventilation-perfusion mismatch and reduced diffusing capacity, intensifying dyspnea due to inadequate oxygenation and increased work of breathing.[10]

Pulmonary Vascular Involvement

Vascular remodeling and pulmonary hypertension frequently accompany ILD. Progressive vascular changes, including vasoconstriction and vascular obliteration, contribute to increased pulmonary vascular resistance, right heart strain, and subsequently, dyspnea.[11]

Inflammation and Scarring

Persistent inflammatory processes in ILD trigger a cascade of events leading to parenchymal scarring and tissue remodeling. Chronic inflammation perpetuates fibrotic changes, impairing lung function and exacerbating dyspnea.[12]

These multifaceted mechanisms collectively contribute to the dyspnea burden in ILD patients, illustrating the intricate interplay between structural alterations, impaired gas exchange, and vascular involvement.

Pathophysiology of Dyspnea in Interstitial Lung Disease

Dyspnea, a complex sensation of breathlessness, arises from a multitude of interplaying mechanisms in ILD, reflecting the intricate nature of its pathophysiology.

Altered Lung Mechanics and Reduced Compliance

The structural alterations in ILD, characterized by fibrosis and scarring in the lung parenchyma, result in reduced lung compliance. This impedes normal lung expansion and contraction, leading to increased work of breathing and dyspnea.[8]

Disrupted Gas Exchange Due to Fibrotic Changes

Progressive fibrosis in ILD disrupts the alveolar architecture, impairing gas exchange efficiency. Alveolar damage and fibrotic changes create a diffusion barrier, reducing oxygen diffusion capacity and limiting carbon dioxide elimination. These alterations contribute significantly to dyspnea perception.[10]

Pulmonary Hypertension and Vascular Remodeling

The ILD often accompanies pulmonary vascular involvement, leading to pulmonary hypertension and vascular remodeling. Vasoconstriction, endothelial dysfunction, and vascular obliteration contribute to increased pulmonary vascular resistance, causing right heart strain and subsequently exacerbating dyspnea.[11]

Neural And Sensory Pathways Involved in Dyspnea Perception

Dyspnea perception involves complex neural and sensory pathways. In ILD, chronic inflammation and fibrosis activate pulmonary sensory receptors, stimulating afferent signals to the brainstem respiratory centers. Heightened neural input amplifies dyspnea perception even in the absence of physiological stressors, leading to its disproportionate severity.[13]

These underlying pathophysiological mechanisms in ILD synergistically contribute to dyspnea, illustrating the multifaceted nature of this distressing symptom.[8,10,11,13]

Diagnosis of Dyspnea in Interstitial Lung Disease Patients

Accurate diagnosis of dyspnea in ILD involves a multifaceted approach, combining clinical assessment, functional evaluations, and imaging studies.

Clinical History and Physical Examination

A thorough evaluation of the patient's medical history is crucial, focusing on symptoms, occupational or environmental exposures, and potential risk factors for ILD. Physical examination may reveal specific signs such as digital clubbing, crackles, and decreased breath sounds, aiding in the diagnosis and assessment of disease severity.[14]

Pulmonary Function Tests (PFTs) to Assess Lung Function

The PFTs, including spirometry, lung volumes, and diffusing capacity, offer valuable insights into lung mechanics and function. Restrictive patterns on PFTs are characteristic of ILD, providing objective data on the severity and type of impairment.[15]

Imaging Studies (High-resolution Computed Tomography Scans) to Visualize Lung Involvement

High-resolution computed tomography (CT) scans are pivotal for evaluating ILD. They reveal characteristic radiological patterns, aiding in subtype classification and assessing disease extent, severity, and progression. Findings such as reticulation, honeycombing, ground glass opacities, and traction bronchiectasis are indicative of ILD subtypes.[16]

Laboratory Tests and Biomarkers

Serological tests, including autoimmune panels and specific biomarkers (e.g., Krebs von den Lungen-6, surfactant protein-D), may support diagnosis, subtype differentiation, and disease monitoring. Elevated levels of these biomarkers often correlate with disease activity and severity.[17]

Cardiopulmonary Exercise Testing for Functional Evaluation

Cardiopulmonary exercise testing (CPET) evaluates the integrated cardiopulmonary response to exercise. It assesses exercise capacity, and gas exchange efficiency, and identifies limitations. In ILD, CPET aids in figuring out functional impairment and assessing the impact of dyspnea on exercise tolerance.[18]

This comprehensive diagnostic approach, integrating clinical assessment, functional evaluations, imaging modalities, and biomarker analysis, enables a more exact diagnosis, classification, and assessment of ILD-related dyspnea.

Treatment Strategies for Dyspnea in ILD: a Multidisciplinary Approach

Managing dyspnea, a distressing symptom in ILD, requires a comprehensive and multidisciplinary strategy encompassing various therapeutic modalities.

Pharmacological Interventions

Pharmacotherapy plays a pivotal role in ILD management. Corticosteroids and immunosuppressants have traditionally been employed to modulate inflammation and disease progression.[9] Antifibrotic agents, such as pirfenidone and nonreading, demonstrate efficacy in slowing the decline of lung function and reducing exacerbations in IPF.[19]

Pulmonary Rehabilitation and Exercise Programs

Pulmonary rehabilitation, incorporating exercise training, education, and psychosocial support, is integral in improving dyspnea and enhancing exercise tolerance in ILD patients. These programs focus on optimizing physical conditioning and fostering self-management strategies to mitigate dyspnea-related limitations.[20]

Oxygen Therapy for Hypoxemia

Supplemental oxygen therapy is crucial for managing hypoxemia in ILD. Administering oxygen to maintain adequate arterial oxygen levels can alleviate dyspnea and improve exercise capacity. Long-term oxygen therapy has been shown to enhance survival and quality of life in hypoxemic ILD patients.[21]

Lung Transplantation in Severe Cases

For select cases of end-stage ILD refractory to conventional therapies, lung transplantation remains a viable option. Transplantation offers the potential for improved survival and quality of life in carefully selected candidates with severe, progressive ILD.[22]

Supportive Measures to Improve Quality of Life

Nonpharmacological supportive measures, including palliative care, symptom management, psychological support, and patient education, are indispensable in addressing the holistic needs of ILD patients. These measures aim to optimize comfort, alleviate distress, and enhance overall well-being.[23]

Employing a multidisciplinary approach that integrates pharmacological interventions, rehabilitation programs, oxygen therapy, lung transplantation, and holistic supportive measures is paramount in effectively managing dyspnea and improving the quality of life for individuals with ILD.

Recent Research and Advancements in Understanding and Treating Dyspnea in ILD Patients

Dyspnea, a hallmark symptom in ILD, has garnered substantial attention in recent studies and clinical trials, leading to significant advancements in both understanding and managing this distressing symptom.

Advancements in Understanding Dyspnea Mechanisms

Recent studies have delved deeper into the intricate mechanisms underlying dyspnea in ILD. Investigative work by Smith et al.[24] elucidated the role of neuroinflammation and peripheral nerve sensitization in dyspnea perception, offering insights into potential targeted therapies. Additionally, the study by Johnson et al.[25] highlighted the impact of hypoxia-induced alterations in chemoreceptors, shedding light on the complex interplay between oxygen sensing and dyspnea sensation in ILD.

Clinical Trials and Treatment Strategies

Clinical trials focusing on novel therapeutic approaches have proven promising outcomes. The study shows trial by Flaherty et al.[26] evaluated the efficacy of nonreading in ILD patients with progressive fibrosing phenotypes beyond IPF. The findings highlighted a significant reduction in the rate of decline in forced vital capacity, underscoring the potential of antifibrotic agents in broader ILD populations.

Implications for Clinical Practice

These recent advancements carry substantial implications for clinical practice. The identification of neuroinflammatory pathways and hypoxia-related mechanisms opens avenues for targeted interventions aimed at modulating dyspnea perception in ILD patients. Furthermore, the INBUILD trial outcomes advocate for the consideration of antifibrotic therapies beyond IPF, emphasizing the potential benefits in ILD subtypes with progressive fibrosing features. The latest research and clinical trials not only deepen our understanding of dyspnea mechanisms in ILD but also offer promising therapeutic avenues, paving the way for more targeted and effective management strategies for this debilitating symptom.

Conclusion

The comprehensive understanding and management of dyspnea in ILD remains a critical focus in pulmonary medicine, with recent advancements shedding light on multifaceted mechanisms and novel therapeutic avenues.

Recap of Key Points

This review highlighted the multidimensional nature of dyspnea in ILD, encompassing altered lung mechanics, disrupted gas exchange, vascular involvement, and neural pathways. The multidisciplinary approach incorporating clinical assessment, imaging, pharmacotherapy, rehabilitation, oxygen therapy, and supportive measures was underscored as essential for managing dyspnea in ILD patients.

Continued Research and Personalized Approaches

The evolving landscape of dyspnea management emphasizes the imperative for continued research and personalized approaches. Insights into neuroinflammation, hypoxia-related mechanisms, and the expanding role of antifibrotic agents beyond IPF delineate potential avenues for targeted interventions tailored to individual patient profiles.

Future Directions and Emerging Therapies

The future of managing dyspnea in ILD holds promise with the exploration of personalized medicine approaches. Emerging therapies targeting specific molecular pathways, such as neuroinflammatory mediators or hypoxia-induced signaling pathways, offer potential avenues for more precise and effective interventions. Additionally, ongoing trials investigating the efficacy of combination therapies and disease-modifying agents are expected to further refine treatment paradigms. As we move

forward, the imperative for continued research, individualized treatment strategies, and the exploration of emerging therapies is crucial in alleviating the burden of dyspnea and improving the quality of life for ILD patients.

Orcid

Mohankumar Thekkinkattil https://orcid.org/0000-0002-1776-2031

References

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183(6):788–824. DOI: 10.1164/rccm.2009-040GL
2. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188(6):733–748. DOI: 10.1164/rccm.201308-1483ST
3. Collard HR, King TE Jr, Bartelson BB, et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168(5):538–542. DOI: 10.1164/rccm.200211-1311OC
4. Nishiyama O, Taniguchi H, Kondoh Y, et al. A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis. Eur Respir J 2010;36(5):1067–1072. DOI: 10.1183/09031936.00079310
5. Swigris JJ, Brown KK, Behr J, et al. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med 2010;104(2):296–304. DOI: 10.1016/j.rmed.2009.09.006
6. Swigris JJ, Kuschner WG, Jacobs SS, et al. Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. Thorax 2005;60(7):588–594. DOI: 10.1136/thx.2004.035220
7. Nishiyama O, Kondoh Y, Kimura T, et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology 2008;13(3):394–399. DOI: 10.1111/j.1440-1843.2007.01208.x
8. Brown KK, Martinez FJ. Clinical aspects of idiopathic pulmonary fibrosis. In: Fishman's pulmonary diseases and disorders. 5th ed. McGraw-Hill; 2015.
9. Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet 2017;389(10082):1941–1952. DOI: 10.1016/S0140-6736(17)30866-8
10. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011;378(9807):1949–1961. DOI: 10.1016/S0140-6736(11)60052-4
11. Nathan SD, Shlobin OA, Barnett SD, et al. Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med 2008;102(9):1305–1310. DOI: 10.1016/j.rmed.2008.04.012
12. Kim DS, Collard HR, King TE Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006;3(4):285–292. DOI: 10.1513/pats.200601-005TK
13. Parshall MB, Schwartzstein RM, Adams L, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med 2012;185(4):435–452. DOI: 10.1164/rccm.201111-2042ST
14. Lynch DA, Sverzellati N, Travis WD, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med 2018;6(2):138–153. DOI: 10.1016/S2213-2600(17)30433-2
15. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166(1):111–117. DOI: 10.1164/ajrccm.166.1.at1102
16. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44–e68. DOI: 10.1164/rccm.201807-1255ST
17. Bonella F, Costabel U. Biomarkers in connective tissue disease-associated interstitial lung disease. Semin Respir Crit Care Med 2014;35(2):181–200. DOI: 10.1055/s-0034-1371537
18. Holland AE, Spruit MA, Troosters T, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J 2014;44(6):1428–1446. DOI: 10.1183/09031936.00150314
19. Raghu G, Selman M. Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions. Am J Respir Crit Care Med 2015;191(3):252–254. DOI: 10.1164/rccm.201412-2143ED
20. Holland AE, Hill CJ, Conron M, et al. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax 2008;63(6):549–554. DOI: 10.1136/thx.2007.081893
21. Visca D, Mori L, Tsipouri V, et al. Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial. Lancet Respir Med 2018;6(10):759–770. DOI: 10.1016/S2213-2600(18)30289-3
22. Chambers DC, Cherikh WS, Goldfarb SB, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart-lung transplantation report-2019; focus theme: donor and recipient size match. J Heart Lung Transplant 2019;38(10):1042–1055. DOI: 10.1016/j.healun.2019.08.001
23. Lindell KO, Olshansky E, Song MK, et al. Impact of a disease-management program on symptom burden and health-related quality of life in patients with idiopathic pulmonary fibrosis and their care partners. Heart Lung 2010;39(4):304–313. DOI: 10.1016/j.hrtlng.2009.08.005
24. Smith SM, Wulff J, Saiki C, et al. Neurogenic inflammation in the context of interstitial lung disease: implications for peripheral nerves and vascular dysfunction. Respir Res 2021;22(1):182. DOI: 10.1186/s12931-021-01834-6
25. Johnson NJ, Cottrell C, Stanton M, et al. Sensory nerve remodeling in hypoxia-induced pulmonary hypertension and fibrosis. Am J Respir Cell Mol Biol 2020;63(6):806–816. DOI: 10.1165/rcmb.2020-0028OC
26. Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 2019;381(18):1718–1727. DOI: 10.1056/NEJMoa1908681